Another recommended policy change to consider is a change in the Hb levels for which ESAs should be avoided in CKD from greater than 12 g/dL to greater than 11.5 g/dL to reflect KDIGO recommendations [24]. This evidence concerns the gene GSTM1 and chronic kidney disease.